Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

BTAI BioXcel Therapeutics

Watchlist
29.750
-1.200-3.88%
Trading Session  01/31 12:44 ET
High
30.810
Open
30.480
Turnover
6.77M
Low
29.140
Pre Close
30.950
Volume
225.50K
Market Cap
833.69M
P/E(TTM)
Loss
52wk High
32.960
Shares
28.02M
P/E(Static)
Loss
52wk Low
8.795
Float Cap
564.01M
Bid/Ask %
-14.29%
Historical High
71.500
Shs Float
18.96M
Volume Ratio
1.51
Historical Low
2.410
Dividend TTM
--
Div Yield TTM
--
P/B
6.57
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.19%
Amplitude
5.39%
Avg Price
30.004
Lot Size
1
Float Cap
564.01M
Bid/Ask %
-14.29%
Historical High
71.500
Shs Float
18.96M
Volume Ratio
1.51
Historical Low
2.410
Dividend TTM
--
P/B
6.57
Dividend LFY
--
Turnover Ratio
1.19%
Amplitude
5.39%
Avg Price
30.004
Lot Size
1
Price Forecast

News

Comment

Company Overview More
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The firm offers IGALMI, a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. It also develops BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of prostate cancer and solid tumors that are refractory to checkpoint inhibitors. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
CEO: Dr. Vimal Mehta, PhD
Market: NASDAQ
Listing Date: 03/08/2018
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist